Incyte Corporation vs SoundHound AI Inc — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while SoundHound AI Inc trades at $6.56 (market cap $2.75B). The key difference: Incyte Corporation is far larger — about 8.4× SoundHound AI Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, SoundHound AI Inc nearer its low. Which is the better fit depends on your goals.
| INCY | SOUN | |
|---|---|---|
Market Cap | $23.11B | $2.75B |
Sector | Health | Technology |
52-Week High | $118.52 | $21.40 |
52-Week Low | $67.38 | $5.90 |
Enterprise Value | $19.13B | $2.54B |
Trailing returns across standard periods
Latest headlines on both assets
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →